RBC Capital Rates Guardant Health (GH) buy, $185 Price Target

RBC Capital continues to back Guardant Health with a buy rating and a target price of $185, a 45.28% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:11 PM EDT · Updated Jun 18, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

RBC Capital rated Guardant Health, Inc. ($GH) "buy" with a $185 price target on June 12, 2026.

Since the rating, $GH is down 2.1% after 1 week, up 20.4% after 1 month and up 20.5% to date (from the $131.62 close on Jun 12, 2026).

GH Guardant Health, Inc.

$158.60 +55.89% year to date

Daily close · Oct 16, 2026

Key Points

RBC Capital reiterated its buy rating on Guardant Health, Inc. (NasdaqGS: GH) on June 12, 2026, with a price target of $185.00.
The stock closed at $127.34 on June 12, significantly below its 52-week high of $183.51, suggesting potential upside.
Guardant Health has a strong analyst consensus rating of 'strong buy' with a mean price target of $196.38 based on 26 analyst opinions.

Get $GH trade alerts by text

We text you when insiders, Congress or big funds trade $GH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Guardant Health, Inc. alert may contain errors. Disclosures

RBC Capital's Continued Support for Guardant Health

RBC Capital reiterated its buy rating on Guardant Health, Inc. (NasdaqGS: GH) on June 12, 2026, with a target price of $185.00. This comes as the stock closed at $127.34 on the same day. The target suggests a significant upside from its current price, reflecting RBC's confidence in the company's future performance.

Why RBC Capital is Optimistic

RBC's decision to maintain its buy rating aligns with the overall positive sentiment surrounding Guardant Health, particularly given its strong revenue growth of 44.3% in the past year. The company's innovative offerings in precision oncology, such as various liquid biopsy tests, position it well in the healthcare sector, despite its current lack of profitability. The stock's price has dipped below its 50-day moving average of $161.34, indicating a potential buying opportunity for investors.

Other Institutional Insights

While there are no recent peer fund activities reported, Guardant Health enjoys a strong analyst consensus. The average target price from 26 analysts stands at $196.38, with estimates ranging from $105.00 to $225.00. This broad range indicates varying expectations for the company's future, but the consensus remains bullish.

Stock Performance Context

Guardant Health's stock trades well below its 52-week high of $183.51, reflecting a potential recovery opportunity. Analysts are closely watching the stock, especially with the next earnings report scheduled for October 28, 2026, which could provide further insights into its financial health and growth trajectory.

12-month forecast

$GH price target

Guardant Health, Inc. daily closes and this analyst's $185 target. Not advice.

Recent Analyst Opinions

In addition to RBC Capital, other firms have maintained positive ratings on Guardant Health. For instance, Morgan Stanley kept an Overweight rating with a target of $200.00 on October 13, 2026, while Barclays also held an Overweight rating with a target of $220.00 on October 7, 2026. These consistent endorsements from multiple analysts enhance the outlook for Guardant Health.

What Guardant Health, Inc. Does

Guardant Health, Inc. is a precision oncology company headquartered in Palo Alto, California. It specializes in blood and tissue tests that assist in cancer diagnosis and treatment. With a growing portfolio of innovative testing solutions, the company plays a crucial role in advancing cancer care.

What's Ahead for Guardant Health, Inc.

Investors will be watching for the upcoming earnings report on October 28, 2026, which may shed light on Guardant Health's financial performance. RBC Capital's buy rating reflects confidence in the company's long-term potential, even as it navigates current market challenges. As always, it's important to remember that analyst ratings and targets are based on past performance and may not reflect current conditions.